Positive News SentimentPositive NewsNASDAQ:SVA Sinovac Biotech (SVA) Stock Price, News & Analysis $6.47 0.00 (0.00%) As of 10/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendNews and TrendsOptions ChainSEC FilingsShort Interest About Sinovac Biotech Stock (NASDAQ:SVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sinovac Biotech alerts:Sign Up Key Stats Today's Range$6.47▼$6.4750-Day Range$6.47▼$6.4752-Week Range$5.73▼$8.75VolumeN/AAverage VolumeN/AMarket Capitalization$644.67 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingBuy Company Overview Sinovac Biotech Ltd. is a biopharmaceutical company focused on the research, development, manufacture and commercialization of vaccines. The company is based in China and develops products for the prevention of infectious diseases in children, adolescents and adults. Its vaccine portfolio has included CoronaVac, an inactivated vaccine for COVID-19; Healive, an inactivated hepatitis A vaccine; Bilive, a combined hepatitis A and B vaccine; and Anflu and Panflu, influenza vaccines. Sinovac has also developed vaccines targeting diseases such as enterovirus 71 and varicella, among others. Founded in 2001, Sinovac has supplied vaccines through China's public immunization programs and private markets and has pursued regulatory approvals and distribution partnerships in international markets. The company has historically been led by Yin Weidong, who has served as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Sinovac Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreSVA MarketRank™: 1.504022154815 of 5 starsSinovac Biotech scored higher than 30% of companies evaluated by MarketBeat, and ranked 767th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingSinovac Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Downside RiskSinovac Biotech has a consensus price target of $1.00, representing about 84.5% downside from its current price of $6.47.Amount of Analyst CoverageSinovac Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Sinovac Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioSinovac Biotech has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Sinovac Biotech has been sold short.Short Interest Ratio / Days to CoverSinovac Biotech has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSinovac Biotech does not currently pay a dividend.Dividend GrowthSinovac Biotech does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentSinovac Biotech has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sinovac Biotech this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Sinovac Biotech to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sinovac Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders12.79% of the stock of Sinovac Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsSinovac Biotech has minimal institutional ownership at this time.Read more about Sinovac Biotech's insider trading history. Receive SVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinovac Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SVA Stock News HeadlinesSinovac Biotech Corporate Event Calendar | NASDAQ:SVAJuly 21, 2026 | benzinga.comSINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash DividendJuly 15, 2026 | businesswire.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 14 at 1:00 AM | Behind the Markets (Ad)SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid ShareholdersJuly 12, 2026 | businesswire.comSinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual ReportJune 15, 2026 | tipranks.comSinovac Biotech Ltd.June 8, 2026 | edition.cnn.comSINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-FJune 5, 2026 | businesswire.comSinovac Faces New Nasdaq Delisting Risk After Regaining ComplianceMay 29, 2026 | tipranks.comSee More Headlines SVA Stock Analysis - Frequently Asked Questions How have SVA shares performed this year? Sinovac Biotech's stock was trading at $6.47 at the beginning of 2026. Since then, SVA stock has increased by 0.0% and is now trading at $6.47. How do I buy shares of Sinovac Biotech? Shares of SVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sinovac Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sinovac Biotech investors own include Tesla (TSLA), Pfizer (PFE), AT&T (T), Moderna (MRNA), OPKO Health (OPK), Astrazeneca (AZN) and BlackBerry (BB). Company Calendar Today10/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (99m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SVA's financial health is in the Red zone, according to TradeSmith. SVA has been in this zone for over 99 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SVA CIK1084201 Webwww.sinovac.com Phone86-10-5693-1800Fax86-10-5693-1800Employees3,008Year Founded2001Price Target and Rating Average Price Target for Sinovac Biotech$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside-84.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio6.07 Quick Ratio5.97 Sales & Book Value Annual Sales$386.01 million Price / Sales1.67 Cash Flow$0.54 per share Price / Cash Flow11.89 Book Value$89.01 per share Price / Book0.07Miscellaneous Outstanding Shares99,640,000Free Float86,894,000Market Cap$644.67 million OptionableOptionable Beta0.76 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:SVA) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...Capital Trends | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
